Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
TLDR
The aim of this review is to discuss some practical aspects of immune therapy, giving to clinicians the concept of immune effector cells balancing between control and tolerance.Abstract:
Cancer cell growth is associated with immune surveillance failure. Nowadays, restoring the desired immune response against cancer cells remains a major therapeutic strategy. Due to the recent advances in biological knowledge, efficient therapeutic tools have been developed to support the best bio-clinical approaches for immune precision therapy. One of the most important successes in immune therapy is represented by the applicational use of monoclonal antibodies, particularly the use of rituximab for B-cell lymphoproliferative disorders. More recently, other monoclonal antibodies have been developed, to inhibit immune checkpoints within the tumor microenvironment that limit immune suppression, or to enhance some immune functions with immune adjuvants through different targets such as Toll-receptor agonists. The aim is to inhibit cancer proliferation by the diminishing/elimination of cancer residual cells and clinically improving the response duration with no or few adverse effects. This effect is supported by enhancing the number, functions, and activity of the immune effector cells, including the natural killer (NK) lymphocytes, NKT-lymphocytes, γδ T-lymphocytes, cytotoxic T-lymphocytes, directly or indirectly through vaccines particularly with neoantigens, and by lowering the functions of the immune suppressive cells. Beyond these new therapeutics and their personalized usage, new considerations have to be taken into account, such as epigenetic regulation particularly from microbiota, evaluation of transversal functions, particularly cellular metabolism, and consideration to the clinical consequences at the body level. The aim of this review is to discuss some practical aspects of immune therapy, giving to clinicians the concept of immune effector cells balancing between control and tolerance. Immunological precision medicine is a combination of modern biological knowledge and clinical therapeutic decisions in a global vision of the patient.read more
Citations
More filters
Journal ArticleDOI
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
Sara Valpione,Elena Galvani,Joshua Tweedy,Piyushkumar A. Mundra,Antonia Banyard,Philippa Middlehurst,Jeff Barry,Sarah Mills,Zena Salih,John Weightman,Avinash Gupta,Gabriela Gremel,Gabriela Gremel,Franziska Baenke,Franziska Baenke,Franziska Baenke,Nathalie Dhomen,Paul Lorigan,Richard Marais +18 more
TL;DR: It is found that early peripheral T cell turnover and TCR repertoire dynamics identified which patients would respond to treatment and the expansion of a subset of immune-effector peripheral T cells the authors call TIE cells correlated with response.
Journal ArticleDOI
Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion.
Jose M. Ayuso,Shujah Rehman,Shujah Rehman,María Virumbrales-Muñoz,Patrick H. McMinn,Peter G. Geiger,Cate M. Fitzgerald,Tiffany M. Heaster,Tiffany M. Heaster,Melissa C. Skala,Melissa C. Skala,David J. Beebe +11 more
TL;DR: In this paper, the authors used an in vitro microfluidic tumor-on-a-chip platform to evaluate how NK cells respond to the tumor-induced suppressive environment.
Journal ArticleDOI
Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer.
TL;DR: In this paper, the authors studied the systemic inflammatory response in both infections and cancer and found that a limited and balanced inflammation initiates the normal immune response, including the adaptive response which amplifies any immunotherapy, including vaccines.
Posted ContentDOI
Statistical Analysis of Spatial Expression Pattern for Spatially Resolved Transcriptomic Studies
TL;DR: The high power of SPARK allows us to identify new genes and pathways that reveal new biology in the data that otherwise cannot be revealed by existing approaches, up to ten times more powerful than existing approaches.
Journal ArticleDOI
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
Yu Chen Chuang,Jen Chih Tseng,Li Rung Huang,Chun Ming Huang,Chi Ying F. Huang,Tsung-Hsien Chuang +5 more
TL;DR: The rationale for combining these two agents is discussed, and evidence indicating the current status of such combination therapy as a novel cancer treatment strategy is presented.
References
More filters
Journal ArticleDOI
Dendritic cells and the control of immunity
TL;DR: Once a neglected cell type, dendritic cells can now be readily obtained in sufficient quantities to allow molecular and cell biological analysis and the realization that these cells are a powerful tool for manipulating the immune system is realized.
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A. Grupp,Michael Kalos,David M. Barrett,Richard Aplenc,David L. Porter,Susan R. Rheingold,David T. Teachey,Anne Chew,Bernd Hauck,J. Fraser Wright,Michael C. Milone,Bruce L. Levine,Carl H. June +12 more
TL;DR: The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.
Journal ArticleDOI
The biology of human natural killer-cell subsets.
TL;DR: Human natural killer cells comprise approximately 15% of all circulating lymphocytes and have the capacity to produce abundant cytokines following activation of monocytes, but has low natural cytotoxicity and is CD16(dim) or CD16(-).